Swedish Orphan Biovitrum AB (publ)

    Jurisdiction
    Sweden
    LEI
    549300124Y3MQI87PT35
    ISIN
    SE0000872095 (SOBI.ST)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    trending_flat 51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €40.99 45.2% undervalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €2.45B
    Gross margin
    78.3%
    EBIT
    €552.14M
    EBIT margin
    22.5%
    Net income
    €397.82M
    Net margin
    16.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €2.86B +16.4% €557.99M +40.3%
    €3.22B +12.8% €725.46M +30.0%
    €3.47B +7.8% €800.91M +10.4%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: July 16, 2025

    Add to watchlist

    Notifications